Ambrilia Biopharma Inc.
TSX : AMB

Ambrilia Biopharma Inc.

June 07, 2007 09:32 ET

Media Advisory: Annual General Meeting of Shareholders-Ambrilia

ATTENTION BUSINESS/FINANCIAL/HEALTH EDITORS

MONTREAL, QUEBEC--(Marketwire - June 7, 2007) - Mr. Stephen G. Sudovar, Executive Chairman and interim CEO of Ambrilia Biopharma Inc. (TSX:AMB) invites the news media to the Annual General and Special Meeting of Shareholders that will be held on Thursday, June 14, 2007, at 10:30 a.m. ET, in the Maxwell-Cummings Auditorium of The Montreal Museum of Fine Arts, 1379 Sherbrooke Street West in Montreal.

Mr. Sudovar will chair the meeting which will be followed by a review of Ambrilia's R&D projects and recent developments, and future outlook. He will be joined by the Company's executive committee.

A brief media session will be held after the meeting at approximately 11:45 a.m. ET, in the Maxwell-Cummings Auditorium.



DATE BOOK:

EVENT: Ambrilia - AGM

DATE: Thursday, June 14, 2007

VENUE: The Montreal Museum of Fine Arts, Auditorium Maxwell-Cummings
1379 Sherbrooke Street W., Montreal

TIME: Annual General Meeting: 10:30 a.m.
Session with Media: 11:45 a.m.
Light Lunch: 12:15 p.m.


Ambrilia will host a live webcast with slides of the event. Interested parties may access the webcast and presentation at www.ambrilia.com, Investors section, Conference calls and webcasts.

ABOUT AMBRILIA BIOPHARMA

Ambrilia Biopharma Inc. (TSX:AMB) is a biopharmaceutical company developing novel small molecules and peptides to treat infectious diseases and cancer. Ambrilia's product portfolio includes promising anti-HIV treatments (PPL-100 and an HIV Integrase Inhibitor Program), two new formulations of existing drugs developed with a patented technology (Octreotide and Goserelin), an anti-cancer therapeutic peptide (PCK3145), a tumor and tumor-vasculature targeting (TVT) technology platform, as well as other anti-virals and immunomodulators. Exclusive worldwide rights to PPL-100 and its related compounds have been granted to Merck & Co., Inc. in return for a $US17 million upfront payment, potential milestones that could reach $US212 million, and royalties. Ambrilia's head office, research and development and manufacturing facilities are located in Montreal with a regional office in France. For more information, please visit the Company's web site: www.ambrilia.com

Contact Information